<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults</title></head>
<body><section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults</h1>
<div class="utdArticleSection" id="topicContentCalculator"><div id="topicText">
<div id="mc3k">
<form action="" id="IPINHL_form" name="IPINHL_form" onreset="rrclr(); document.getElementById('inputchk').innerHTML=inputchktxt; " onsubmit="return false;">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">

 
Calculator: International Prognostic Index for non-Hodgkin lymphoma in adults
</span></td></tr></tbody></table><br/> <br/>
<div id="calc_main">
<div id="calc_input">
<center>
<table cellpadding="3" cellspacing="0" summary="EBMcalc Table">
<tbody><tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Age &gt;60 years old (1 point)" id="togel1" name="cc1" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel1');">Age &gt;60 years old (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Serum lactate dehydrogenase concentration above normal (1 point)" id="togel2" name="cc2" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel2');">Serum lactate dehydrogenase concentration above normal (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate Ann Arbor stage III or IV (1 point)" id="togel3" name="cc3" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel3');">Ann Arbor stage III or IV (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right" valign="top"><input aria-label="Check this box to indicate More than one extranodal disease site (1 point)" id="togel4" name="cc4" onclick="IPINHL_fx();" type="checkbox"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="togCB('togel4');">More than one extranodal disease site (1 point)</span></td></tr>
<tr><td align="left" colspan="3"><span class="medCalcFontCCTabBold">ECOG performance scale </span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 0: Fully active; no performance restrictions (0 points)" id="togel5" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel5');"> Performance status 0: Fully active; no performance restrictions (0 points)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)" id="togel6" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel6');"> Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours (1 point)" id="togel7" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel7');"> Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50% of waking hours (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours (1 point)" id="togel8" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel8');"> Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50% of waking hours (1 point)</span></td></tr>
<tr><td width="20"><br/></td>
<td align="right"><input aria-label="This button selects an option for: ECOG performance scale. The option is  Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)" id="togel9" name="cc5" onclick="IPINHL_fx();" type="radio"/></td>
<td align="left"><span class="medCalcFontOneClick" onclick="setRB('togel9');"> Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)</span></td></tr>
</tbody></table>
<span class="medCalcFontOne" id="inputchk"><br/> <br/><b>Important:</b> Inputs must be complete to perform calculation. <br/></span>
</center>
</div>
<br/> <br/>
<div id="calc_result">
<span class="medCalcFontCCTabBold">
Total criteria point count:
</span>
<input aria-label="This box holds the total criteria point count" aria-readonly="true" name="cctotal" size="6" type="text"/><br/> <br/>
<center><input name="reset" type="reset" value="Reset form"/> </center>
<br/> <br/>
<div aria-label="This table highlights the result When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:. No result is highlighted" id="rr1_tag" tabindex="0">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">


When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:
</span></td></tr></tbody></table><br/> <br/>
</div>
<center>
<table border="1" cellpadding="4" cellspacing="0" summary="RRTable">
<tbody><tr id="rr1_1"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">0 to 1 point:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne">Low risk with 73% 5-year OS and 87% CR</span></td></tr>
<tr id="rr1_2"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">2 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> Low-intermediate risk with 51% 5-year OS and 67% CR</span></td></tr>
<tr id="rr1_3"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">3 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> High-intermediate risk with 43% 5-year OS and 55% CR</span></td></tr>
<tr id="rr1_4"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">4 to 5 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> High risk with 26% 5-year OS and 44% CR</span></td></tr>
</tbody></table>
</center>
<br/> <br/>
<br/> <br/>
<div aria-label="This table highlights the result When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:. No result is highlighted" id="rr2_tag" tabindex="0">
<table cellpadding="4" cellspacing="0" summary="EBMcalc Table" width="100%">
<tbody><tr><td bgcolor="#eeeeee" width="1%"><br/></td>
<td align="left" bgcolor="#eeeeee">
<span class="medCalcFontTitleBox">


When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:
</span></td></tr></tbody></table><br/> <br/>
</div>
<center>
<table border="1" cellpadding="4" cellspacing="0" summary="RRTable">
<tbody><tr id="rr2_5"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">0 to 1 point:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 81%, PFS 87%, and OS 91%</span></td></tr>
<tr id="rr2_6"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">2 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 69%, PFS 75%, and OS 81%</span></td></tr>
<tr id="rr2_7"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">3 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 53%, PFS 59%, and OS 65%</span></td></tr>
<tr id="rr2_8"><td align="right" nowrap="nowrap" style="border-right: 0px;"><span class="medCalcFontOneBold">4 to 5 points:</span></td>
<td align="left" style="border-left: 0px;"><span class="medCalcFontOne"> EFS 50%, PFS 50%, and OS 59%</span></td></tr>
</tbody></table>
</center>
<br/> <br/>
</div>
</div>
<div id="calc_notes">
<span class="medCalcFontOneBold">Notes</span>
<ul class="medCalcFontOne">
<li><b>ECOG</b>: Eastern Cooperative Oncology Group; <b>NHL</b>: Non-Hodgkin lymphoma.</li>
</ul>
</div>
<br/> <br/>
<div id="calc_refs">
<span class="medCalcFontRef"><b>References</b></span>
<ol>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/8141877" style="color: green; text-decoration: none;" target="_blank">The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive  non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/20385988" style="color: green; text-decoration: none;" target="_blank">Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid  predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.  J Clin Oncol 2010; 28:2373. Erratum in: J Clin Oncol 2011; 29:779.</a></span></li>
<li><span class="medCalcFontRef"><a href="https://www.ncbi.nlm.nih.gov/pubmed/7165009" style="color: green; text-decoration: none;" target="_blank">Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.  Am J Clin Oncol 1982; 5:649.</a></span></li>
</ol>
</div>
</form>
</div>
<span class="calculatorVendorId" id="T1678215873">
</span></div><div id="printDisclaimer">
<b>Only digits 0 to 9 and a single decimal point (".") are acceptable as numeric inputs. Attempted input of other characters into a numeric field may lead to an incorrect result.</b>
<p>
	Information on this page may not appear correctly if printed. </p>
</div>
<div id="disclaimerCalculator">
<div class="medCalcFontTwo">
<p class="header">Legal Notices and Disclaimer</p>
<p>
			All information contained in and produced by the EBMcalc system is provided
			for educational purposes only. This information should not be used for the diagnosis or treatment
			of any health problem or disease. 
			<b>THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.</b>
<a class="medCalcDisclaimerLink" href="/legal/ebmcalc-disclaimer">Click here for full notice and disclaimer.</a>
</p>
<p class="copy">EBMcalc is Copyright © 1998-2024 Foundation Internet Services, LLC</p>
</div>
</div><div id="topicVersionRevision">Topic 87307 Version 8.0</div></div>
</div>
</div>
</section><script>
/* <![CDATA[ */


var curelement;

function togCB(thisid){
thischeckbox = document.getElementById(thisid);
if (thischeckbox.checked){ thischeckbox.checked = false; }
else { thischeckbox.checked = true; }
IPINHL_fx();
}

function setRB(thisid){
document.getElementById(thisid).checked = true;
IPINHL_fx();
}


/* ]]> */

/* <![CDATA[ */





var inputchktxt = '<br />&nbsp;<br /><b>Important:</b> Inputs must be complete to perform calculation. <br />'


var calctxt = '';
var xmltxt = '';
var xmlresult = '';
var htmtxt = '';
var postNow = false;
var printing = false;
var rbchk = false;


function IPINHL_fx() {
with(document.IPINHL_form){

Score = 0.0;
doCalc = true;

if (cc1.checked){
Score = Score + 1;
}
if (cc2.checked){
Score = Score + 1;
}
if (cc3.checked){
Score = Score + 1;
}
if (cc4.checked){
Score = Score + 1;
}
rbchk = false;
if (cc5[0].checked){
rbchk = true; Score = Score + 0; 
}
if (cc5[1].checked){
rbchk = true; Score = Score + 0; 
}
if (cc5[2].checked){
rbchk = true; Score = Score + 1; 
}
if (cc5[3].checked){
rbchk = true; Score = Score + 1; 
}
if (cc5[4].checked){
rbchk = true; Score = Score + 1; 
}
if (!rbchk) doCalc = false;
if (doCalc){
cctotal.value = Score;
if (cctotal.value == 'NaN') cctotal.value = '';
}
else{
Score = null;
cctotal.value = '';
if (typeof rrclr == 'function') { rrclr(); };
document.IPINHL_form.cctotal.value = '';
}

if (doCalc) document.getElementById('inputchk').innerHTML = '';
else document.getElementById('inputchk').innerHTML = inputchktxt;



if (doCalc){
rrclr();
if (( Score >= 0) && ( Score <= 1)){ document.getElementById('rr1_1').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 0 to 1 point: Low risk with 73% 5-year OS and 87% CR';
calctxt += '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 0 to 1 point: Low risk with 73% 5-year OS and 87% CR';
xmltxt += '\n<Result_Interpretation>When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 0 to 1 point: Low risk with 73% 5-year OS and 87% CR<\/Result_Interpretation>\n';
}
if (( Score >= 2) && ( Score <= 2)){ document.getElementById('rr1_2').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 2 points:  Low-intermediate risk with 51% 5-year OS and 67% CR';
calctxt += '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 2 points:  Low-intermediate risk with 51% 5-year OS and 67% CR';
xmltxt += '\n<Result_Interpretation>When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 2 points:  Low-intermediate risk with 51% 5-year OS and 67% CR<\/Result_Interpretation>\n';
}
if (( Score >= 3) && ( Score <= 3)){ document.getElementById('rr1_3').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 3 points:  High-intermediate risk with 43% 5-year OS and 55% CR';
calctxt += '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 3 points:  High-intermediate risk with 43% 5-year OS and 55% CR';
xmltxt += '\n<Result_Interpretation>When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 3 points:  High-intermediate risk with 43% 5-year OS and 55% CR<\/Result_Interpretation>\n';
}
if (( Score >= 4) && ( Score <= 5)){ document.getElementById('rr1_4').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 4 to 5 points:  High risk with 26% 5-year OS and 44% CR';
calctxt += '\n\nWhen applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 4 to 5 points:  High risk with 26% 5-year OS and 44% CR';
xmltxt += '\n<Result_Interpretation>When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:: 4 to 5 points:  High risk with 26% 5-year OS and 44% CR<\/Result_Interpretation>\n';
}
if ((Score >= 0) && (Score <= 1)){ document.getElementById('rr2_5').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 0 to 1 point:  EFS 81%, PFS 87%, and OS 91%';
calctxt += '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 0 to 1 point:  EFS 81%, PFS 87%, and OS 91%';
xmltxt += '\n<Result_Interpretation>When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 0 to 1 point:  EFS 81%, PFS 87%, and OS 91%<\/Result_Interpretation>\n';
}
if ((Score >= 2) && (Score <= 2)){ document.getElementById('rr2_6').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 2 points:  EFS 69%, PFS 75%, and OS 81%';
calctxt += '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 2 points:  EFS 69%, PFS 75%, and OS 81%';
xmltxt += '\n<Result_Interpretation>When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 2 points:  EFS 69%, PFS 75%, and OS 81%<\/Result_Interpretation>\n';
}
if ((Score >= 3) && (Score <= 3)){ document.getElementById('rr2_7').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 3 points:  EFS 53%, PFS 59%, and OS 65%';
calctxt += '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 3 points:  EFS 53%, PFS 59%, and OS 65%';
xmltxt += '\n<Result_Interpretation>When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 3 points:  EFS 53%, PFS 59%, and OS 65%<\/Result_Interpretation>\n';
}
if ((Score >= 4) && (Score <= 5)){ document.getElementById('rr2_8').bgColor = '#8ab2be';
interptxt = '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 4 to 5 points:  EFS 50%, PFS 50%, and OS 59%';
calctxt += '\n\nWhen applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 4 to 5 points:  EFS 50%, PFS 50%, and OS 59%';
xmltxt += '\n<Result_Interpretation>When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:: 4 to 5 points:  EFS 50%, PFS 50%, and OS 59%<\/Result_Interpretation>\n';
}
document.getElementById('rr2_tag').ariaLabel = interptxt;
interptxt = '';


}
}
}




function rrclr(){
document.getElementById('rr1_1').bgColor = '';
document.getElementById('rr1_2').bgColor = '';
document.getElementById('rr1_3').bgColor = '';
document.getElementById('rr1_4').bgColor = '';
document.getElementById('rr1_tag').ariaLabel = "This table highlights the result When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5-year overall survival (OS) and complete response (CR) rates were as follows:. No result is highlighted"; interptxt = '';
document.getElementById('rr2_5').bgColor = '';
document.getElementById('rr2_6').bgColor = '';
document.getElementById('rr2_7').bgColor = '';
document.getElementById('rr2_8').bgColor = '';
document.getElementById('rr2_tag').ariaLabel = "This table highlights the result When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3-year event-free survival (EFS),  progression-free survival (PFS), and overall survival (OS) were as follows:. No result is highlighted"; interptxt = '';
}




/* ]]> */

/* <![CDATA[ */







function loadQueryParams(thisqs){
if (thisqs) alert('Data panel values cannot be transferred to this calculator.');
return;
}


/* ]]> */
</script><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="https://medilib.ir/assets/js/jquery.min.js"></script><script src="https://medilib.ir/assets/js/popper.min.js"></script><script src="https://medilib.ir/assets/js/bootstrap.min.js"></script><script src="https://medilib.ir/assets/js/classy-nav.min.js"></script><script src="https://medilib.ir/assets/js/owl.carousel.min.js"></script><script src="https://medilib.ir/assets/js/jquery.magnific-popup.min.js"></script><script src="https://medilib.ir/assets/js/jquery.counterup.min.js"></script><script src="https://medilib.ir/assets/js/waypoints.min.js"></script><script src="https://medilib.ir/assets/js/form-validator.min.js"></script><script src="https://medilib.ir/assets/js/contact-form-script.js"></script><script src="https://medilib.ir/assets/js/main.js"></script><script async="" src="https://www.googletagmanager.com/gtag/js?id=G-WFDJ5JLM3Q"></script><script>
    window.addEventListener("load", () => {

        if ('serviceWorker' in navigator) {
            navigator.serviceWorker.getRegistrations().then(function (registrations) {
                //returns installed service workers
                if (registrations.length) {
                    for (let registration of registrations) {
                        if (
                            registration.active.scriptURL.startsWith("/serviceWorker.js") &&
                            !registration.active.scriptURL.endsWith("/serviceWorker.js?v=18")
                        ) {
                            registration.unregister();
                        }
                    }
                }
            });
            navigator.serviceWorker.register('/serviceWorker.js?v=18', {
                scope: '/'
            })
                .then(function (registration) {
                    console.log('Registration successful, scope is:', registration.scope);
                })
                .catch(function (error) {
                    console.log('Service worker registration failed, error:', error);
                });
        }
    });
    const promptElement = document.querySelector('.pwaprompt');
    const footerPromptElement = document.querySelector('#footerPromptElement');
    const scrollTopElement = document.querySelector('.scrolltop');
    // const installButton = promptElement.querySelector('.prompt__install');
    const closeButton = promptElement.querySelector('.prompt__close');
    let installEvent;

    function setWithExpiry(key, value, seconds) {
        const now = new Date()

        // `item` is an object which contains the original value
        // as well as the time when it's supposed to expire
        const item = {
            value: value,
            expiry: now.getTime() + (seconds * 1000),
        }
        localStorage.setItem(key, JSON.stringify(item))
    }

    function getWithExpiry(key) {
        const itemStr = localStorage.getItem(key)
        // if the item doesn't exist, return null
        if (!itemStr) {
            return null
        }
        const item = JSON.parse(itemStr)
        const now = new Date()
        // compare the expiry time of the item with the current time
        if (now.getTime() > item.expiry) {
            // If the item is expired, delete the item from storage
            // and return null
            localStorage.removeItem(key)
            return null
        }
        return item.value
    }

    // checks if the localStorage item has been set
    function getVisited() {
        return getWithExpiry('install-prompt')
        // return localStorage.getItem('install-prompt');
    }

    // sets the localStorage item
    function setVisited() {
        fiveDay = 5 * (24 * (60 * 60))
        setWithExpiry('install-prompt', true, fiveDay)
        // localStorage.setItem('install-prompt', true);
    }

    closeButton.addEventListener('click', () => {
        // set localStorage to true
        setVisited();

        // hide the prompt banner
        promptElement.style.display = 'none';
        scrollTopElement.style.bottom = '30px';

        // installEvent = null;
    });
    // Detects if device is on iOS
    const isIos = () => {
        const userAgent = window.navigator.userAgent.toLowerCase();
        return /iphone|ipad|ipod/.test(userAgent);
    }
    // Detects if device is in standalone mode
    const isInStandaloneMode = () => ('standalone' in window.navigator) && (window.navigator.standalone);

    // Checks if should display install popup notification:
    if (isIos() && !isInStandaloneMode()) {
        if (!getVisited()) {
            promptElement.style.display = 'block';
            scrollTopElement.style.bottom = '80px';
        }
        footerPromptElement.style.display = 'block';
    }


    // this event will only fire if the user does not have the pwa installed
    window.addEventListener('beforeinstallprompt', (event) => {
        event.preventDefault();
        // if no localStorage is set, first time visitor
        if (!getVisited()) {
            // show the prompt banner
            promptElement.style.display = 'block';
            scrollTopElement.style.bottom = '80px';

            // store the event for later use

        }
        footerPromptElement.style.display = 'block';
        installEvent = event;

    });
    $(document).on('click', '.prompt__install', function () {
        promptElement.style.display = 'none';
        scrollTopElement.style.bottom = '30px';

        if (isIos() && !isInStandaloneMode()) {
            setVisited();
            $('#iphoneAddToHomeScreen').modal()
        } else {

            // trigger the prompt to show to the user
            installEvent.prompt();
            // check what choice the user made
            installEvent.userChoice.then((choice) => {
                // if the user declined, we don't want to show the button again
                // set localStorage to true
                if (choice.outcome !== 'accepted') {
                    setVisited();
                }

                installEvent = null;
            });
        }

    });
</script><script>

    window.dataLayer = window.dataLayer || [];

    function gtag() {
        dataLayer.push(arguments);
    }

    gtag('js', new Date());

    gtag('config', 'G-WFDJ5JLM3Q');
</script><script>
      var topicReferences=[];

      function refrence(id) {
          var myReference=Object.values(topicReferences)[id];
          console.log(myReference);
          $("#pmid").attr("href",myReference['pmid']);
          if (typeof myReference['description'] !== 'undefined' && myReference['description']!="") {
            $("#myModalLabel34").html('Description : <p>' + myReference['description'] + "</p>");
          }
          if (typeof myReference['authors'] !== 'undefined' && myReference['authors']!="") {
            $("#referenceAuthors").html('Authors : <p>' + myReference['authors'] + "</p>");
          }
          if (typeof myReference['source'] !== 'undefined' && myReference['source']!="") {
            $("#referenceSource").html('Source : <p>' + myReference['source'] + "</p>");
          }
          if (typeof myReference['title'] !== 'undefined' && myReference['title']!="") {
            $("#referenceTitle").html('Title : <p>' + myReference['title'] + "</p>");
          }
          if (typeof myReference['affiliation'] !== 'undefined' && myReference['affiliation']!="") {
            $("#referenceAffiliation").html('Affiliation : <p>' + myReference['affiliation'] + "</p>");
          }
      }
  </script><script>

      var screenHeight = screen.height;

      if (screenHeight > 700) {
        // $document.getElementById("Uptodate_image").style.width = "100% !important;";
        // $('.Uptodate_image').css('width', '100% !important;');
        console.log("more");
      }else{
        console.log(screenHeight);
      }
    $(document).scroll(function()  {
      var y = $(this).scrollTop();
      if (y > 100) {
        $('.goback').fadeIn();
        $('.buyPackage').fadeIn();
        // alert(document.getElementById('main_menu').style.zIndex);
        document.getElementById("uptodate-area").style.padding = "0px 0 0 0";
        document.getElementById('main_menu').style.zIndex=1;
         document.getElementById('main_menu').style.display="none";
        document.getElementById('navbar_menu').style.marginTop="70px"
        document.getElementById('uptodate-area').style.marginTop="0px"
        document.getElementById('uptodate-area').style.zIndex=999;
        console.log('down');
      } else {
        $('.goback').fadeOut();
        $('.buyPackage').fadeOut();
        document.getElementById("uptodate-area").style.padding = "0px 0 0 0";
        document.getElementById('navbar_menu').style.marginTop="0px"
        document.getElementById('main_menu').style.display="";
        document.getElementById('uptodate-area').style.zIndex=0;
        console.log('up');
      }
    });
    function goBack() {
      window.history.back();
    }
    function buyPackage() {
      window.open("https://medilib.ir/userPanel/package/uptodate/index",'_blank');
    }
  </script></body>
</html>
